These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31852847)

  • 21. Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
    Barker RG; Wyckelsma VL; Xu H; Murphy RM
    Am J Physiol Cell Physiol; 2018 Apr; 314(4):C483-C491. PubMed ID: 29351413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy.
    Howard ZM; Gomatam CK; Rabolli CP; Lowe J; Piepho AB; Bansal SS; Accornero F; Rafael-Fortney JA
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.
    González-Sánchez J; Sánchez-Temprano A; Cid-Díaz T; Pabst-Fernández R; Mosteiro CS; Gallego R; Nogueiras R; Casabiell X; Butler-Browne GS; Mouly V; Relova JL; Pazos Y; Camiña JP
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1063-1078. PubMed ID: 30216693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Glucocorticoids in Murine Models of Duchenne and Limb-Girdle Muscular Dystrophy.
    Wintzinger M; Miz K; York A; Demonbreun AR; Molkentin JD; McNally EM; Quattrocelli M
    Methods Mol Biol; 2023; 2587():467-478. PubMed ID: 36401044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle.
    Hammers DW; Hart CC; Patsalos A; Matheny MK; Wright LA; Nagy L; Sweeney HL
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents.
    Herbelet S; Rodenbach A; Paepe B; De Bleecker JL
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy.
    Guerron AD; Rawat R; Sali A; Spurney CF; Pistilli E; Cha HJ; Pandey GS; Gernapudi R; Francia D; Farajian V; Escolar DM; Bossi L; Becker M; Zerr P; de la Porte S; Gordish-Dressman H; Partridge T; Hoffman EP; Nagaraju K
    PLoS One; 2010 Jun; 5(6):e11220. PubMed ID: 20574530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microbes, metabolites and muscle: Is the gut-muscle axis a plausible therapeutic target in Duchenne muscular dystrophy?
    Marullo AL; O'Halloran KD
    Exp Physiol; 2023 Sep; 108(9):1132-1143. PubMed ID: 37269541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy.
    Dubinin MV; Talanov EY; Tenkov KS; Starinets VS; Belosludtseva NV; Belosludtsev KN
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth Hormone Increases Bone Toughness and Decreases Muscle Inflammation in Glucocorticoid-Treated Mdx Mice, Model of Duchenne Muscular Dystrophy.
    Yoon SH; Grynpas MD; Mitchell J
    J Bone Miner Res; 2019 Aug; 34(8):1473-1486. PubMed ID: 31188496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma lipidomic analysis shows a disease progression signature in mdx mice.
    Tsonaka R; Seyer A; Aartsma-Rus A; Spitali P
    Sci Rep; 2021 Jun; 11(1):12993. PubMed ID: 34155298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.
    Escolar DM; Hache LP; Clemens PR; Cnaan A; McDonald CM; Viswanathan V; Kornberg AJ; Bertorini TE; Nevo Y; Lotze T; Pestronk A; Ryan MM; Monasterio E; Day JW; Zimmerman A; Arrieta A; Henricson E; Mayhew J; Florence J; Hu F; Connolly AM
    Neurology; 2011 Aug; 77(5):444-52. PubMed ID: 21753160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Klotho gene silencing promotes pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Wehling-Henricks M; Li Z; Lindsey C; Wang Y; Welc SS; Ramos JN; Khanlou N; Kuro-O M; Tidball JG
    Hum Mol Genet; 2016 Jun; 25(12):2465-2482. PubMed ID: 27154199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
    Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy.
    Hibaoui Y; Reutenauer-Patte J; Patthey-Vuadens O; Ruegg UT; Dorchies OM
    J Pineal Res; 2011 Sep; 51(2):163-71. PubMed ID: 21486366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decrease of myofiber branching via muscle-specific expression of the olfactory receptor mOR23 in dystrophic muscle leads to protection against mechanical stress.
    Pichavant C; Burkholder TJ; Pavlath GK
    Skelet Muscle; 2016; 6():2. PubMed ID: 26798450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of PDE5 inhibition on dystrophic muscle following an acute bout of downhill running and endurance training.
    Batra A; Vohra RS; Chrzanowski SM; Hammers DW; Lott DJ; Vandenborne K; Walter GA; Forbes SC
    J Appl Physiol (1985); 2019 Jun; 126(6):1737-1745. PubMed ID: 30946638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.